Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn’s Disease With up to 6 Years of Follow-Up in the Pyramid Registry

Overview of attention for article published in American Journal of Gastroenterology, June 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter: 35 X users
reddit: 1 Redditor

guideline: 1 clinical guideline source

Readers on

mendeley: 86 Mendeley

So far, Altmetric has seen 38 X posts from 35 X users, with an upper bound of 123,335 followers.

Important to remember •#PYRAMID Risk of lymphoma w #adalimumab /TNFi does not ⬆️ w time @AmCollegeGastro @EdwardLoftus2 https://t.co/ioL5KXwJI2 •#STORI @AGA_CGH https://t.co/qlhMYtit3C Only 1/5 pts stayed off antiTNF at 7yrs w/o complication, But while m…

RT @DCharabaty: Real world long term safety of #Humira: PYRAMID study: More than 5,000 #Crohns patients on #adalimumab followed up to 6 yea…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 34 additional X posts.